Cancer immunotherapy using cells modified with cytokine genes

• Autorzy: Kowalczyk D. W. , Wysocki P.J. , Mackiewicz A.
• Języki publikacji: EN

Abstrakty

EN

The ability of various cytokines to hamper tumor growth or to induce anti-tumor im­mune response has resulted in their study as antitumor agents in gene therapy ap­proaches. In this review we will concentrate on the costimulation of antitumor immune re­sponses using modification of various cell types by cytokine genes. Several strategies have emerged such as (i) modification of tumor cells with cytokine genes ex vivo (whole tumor cell vaccines), (ii) ex vivo modification of other cell types for cytokine gene delivery, (iii) delivery of cytokine genes into tumor microenvironment in vivo, (iv) modification of dendritic cells with cytokine genes ex vivo. Originally single cytokine genes were used. Subsequently, multiple cytokine genes were applied simul­taneously, or in combination with other factors such as chemokines, membrane bound co-stimulatory molecules, or tumor associated antigens. In this review we dis­cuss these strategies and their use in cancer treatment as well as the promises and lim­itations of cytokine based cancer gene therapy. Clinical trials, including our own expe­rience, employing the above strategies are discussed.

Słowa kluczowe

EN

gene therapy; dendritic cell; cytokine; cancer vaccine; antitumour immune response; antitumour agent; tumour growth; cancer; immunotherapy

• Wydawca: -
• Czasopismo: Acta Biochimica Polonica
• Rocznik: 2003
• Tom: 50
• Numer: 3
• Opis fizyczny: p.613-624

Twórcy

autor

Kowalczyk D. W.

• University of Medical Sciences, Garbary 15, 61-866 Poznan, Poland

autor

Wysocki P.J.

autor

Mackiewicz A.

Bibliografia

• Albert ML, Sauter B, Bhardwaj N. (1998) Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature.; 392: 86-9.
• Baratin M, Ziol M, Romieu R, Kayibanda M, Gouilleux F, Briand P, Leroy P, Haddada H, Renia L, Viguier M, Guillet JG. (2001) Regression of primary hepatocarcinoma in cancer-prone transgenic mice by local interferon-gamma delivery is associated with macrophages recruitment and nitric oxide production. Cancer Gene Ther.; 8: 193-202.
• Basse PH, Whiteside TL, Herberman RB. (2000) Use of activated natural killer cells for tumor immunotherapy in mouse and human. Methods Mol Biol.; 121: 81-94.
• Bennett SR, Carbone FR, Karamalis F et al. (1998) Help for cytotoxic-T-cell responses is mediated by CD40 signalling. Nature.; 393: 478-80.
• Burnet FM.(1978) Cancer: somatic-genetic considerations. Adv Cancer Res.; 28: 1-29.
• Caux C, Massacrier C, Vanbervliet B et al. (1994) Activation of human dendritic cells through CD40 cross-linking. J Exp Med.; 180: 1263-72.
• Cella M, Scheidegger D, Palmer-Lehmann K et al. (1996) Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med.; 184: 747-52.
• Chang EY, Chen CH, Ji H, Wang TL, Hung K, Lee BP, Huang AY, Kurman RJ, Pardoll DM, Wu T. (2000) Antigen- specific cancer immunotherapy using a GM-CSF secreting allogeneic tumor cell-based vaccine. Int J Cancer.; 86: 725-30.
• Corr M, Lee DJ, Carson DA, Tighe H. (1996) Gene vaccination with naked plasmid DNA: mechanism of CTL priming. J Exp Med.; 184: 1555-60.
• Coulie PG, van der Bruggen P. (2003) T-cell responses of vaccinated cancer patients. Curr Opin Immunol.; 15: 131-7.
• Curiel-Lewandowski C, Mahnke K, Labeur M et al. (1999) Transfection of immature murine bone marrow-derived dendritic cells with the Granulocyte-Macrophage Colony-Stimulating Factor gene potently enhances their in vivo antigen- presenting capacity. J Immunol.; 163: 174-83.
• Doe B, Selby M, Barnett S, Baenziger J, Walker CM. (1996) Induction of cytotoxic T lymphocytes by intramuscular immunization with plasmid DNA is facilitated by bone marrow-derived cells. Proc Natl Acad Sci U S A.; 93: 8578-83.
• Dranoff G. (2002) GM-CSF-based cancer vaccines. Immunol Rev.; 188: 147-54.
• Fathallah-Shaykh HM, Zhao LJ, Kafrouni AI, Smith GM, Forman J. (2000) Gene transfer of IFN-gamma into established brain tumors represses growth by antiangiogenesis. J Immunol.; 164: 217-22.
• Fernandez NC, Levraud JP, Haddada H, Perricaudet M, Kourilsky P. (1999) High frequency of specific CD8+ T cells in the tumor and blood is associated with efficient local IL-12 gene therapy of cancer. J Immunol.; 162: 609-17.
• Furumoto K, Arii S, Yamasaki S et al. (2000) Spleen-derived dendritic cells engineered to enhance interleukin-12 production elicit therapeutic antitumor immune responses. Int J Cancer.; 5: 665-72.
• Harrington K, Alvarez-Vallina L, Crittenden M, Gough M, Chong H, Diaz RM, Vassaux G, Lemoine N, Vile R. (2002) Cells as vehicles for cancer gene therapy: the missing link between targeted vectors and systemic delivery? Hum Gene Ther.; 13: 1263-80.
• He Z, Wlazlo AP, Kowalczyk DW, Cheng J, Xiang ZQ, Giles-Davis W, Ertl HC. (2000) Viral recombinant vaccines to the E6 and E7 antigens of HPV-16. Virology.; 270: 146-61.
• Huang AY, Bruce AT, Pardoll DM, Levitsky HI. (1996) Does B7-1 expression confer antigen-presenting cell capacity to tumors in vivo? J Exp Med.; 183: 769-76.
• Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. (1994b) Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. Science.; 264: 961-5.
• Huang AY, Golumbek P, Ahmadzadeh M, Jaffee E, Pardoll D, Levitsky H. (1994) Bone marrow-derived cells present MHC class I-restricted tumour antigens in priming of antitumour immune responses. Ciba Found Symp.; 187: 229-40.
• Hurford JRK, Dranoff G, Mulligan RC, Tepper RI. (1995) Gene therapy of metastatic cancer by in vivo retroviral gene targeting. Nat Genet.; 10: 430-5.
• Itoh Y, Koshita Y, Takahashi M, Watanabe N, Kohgo Y, Niitsu Y. (1995) Characterization of tumor-necrosis-factor-gene- transduced tumor-infiltrating lymphocytes from ascitic fluid of cancer patients: analysis of cytolytic activity, growth rate, adhesion molecule expression and cytokine production. Cancer Immunol Immunother.; 40: 95-102.
• Jager E, Jager D, Knuth A. (2002) Clinical cancer vaccine trials. Curr Opin Immunol.; 14: 178-82.
• Kikuchi T, Moore MA, Crystal RG. (2000) Dendritic cells modified to express CD40 ligand elicit therapeutic immunity against preexisting murine tumors. Blood.; 96: 91-9.
• Kjaergaard J, Shu S. (1999) Tumor infiltration by adoptively transferred T cells is independent of immunologic specificity but requires down-regulation of L-selectin expression. J Immunol.; 163: 751-9.
• Kowalczyk DW. (2002) Tumors and the danger model. Acta Biochim Pol.; 49: 295-302.
• Kowalczyk DW, Wlazlo AP, Giles-Davis W, Ertl HC. (2000) Staining of antigen activated lymphocytes (SAAL): a highly specific method for flow cytometric quantitation of tumor-specific CD8(+) T cells. J Immunol Methods. ; 241: 131-9.
• Kowalczyk DW, Wlazlo AP, Blaszczyk-Thurin M, Xiang ZQ, Giles-Davis W, Ertl HC. (2001) A method that allows easy characterization of tumor-infiltrating lymphocytes. J Immunol Methods.; 253: 163-75.
• Levitsky HI, Lazenby A, Hayashi RJ, Pardoll DM. (1994) In vivo priming of two distinct antitumor effector populations: the role of MHC class I expression. J Exp Med.; 179: 1215-24.
• Liu Y, Huang H, Saxena A, Xiang J. (2002) Intratumoral coinjection of two adenoviral vectors expressing functional interleukin-18 and inducible protein-10, respectively, synergizes to facilitate regression of established tumors. Cancer Gene Ther.; 9: 533-42.
• Mackiewicz A, Gorny A, Laciak M, Malicki J, Murawa P, Nowak J, Wiznerowicz M, Hawley RG, Heinrich PC, Rose-
• John S. (1995) Gene therapy of human melanoma. Immunization of patients with autologous tumor cells admixed with allogeneic melanoma cells secreting interleukin 6 and soluble interleukin 6 receptor. Hum Gene Ther.; 6: 805-11.
• Mackiewicz A, Rose-John S. (1998) More about genetically modified tumour vaccines. Gene Ther.; 5: 147-8.
• Matzinger P. (1994) Tolerance, danger, and the extended family. Annu Rev Immunol.; 12: 991-1045.
• Matzinger P. (2002) The danger model: a renewed sense of self. Science.; 296: 301-5.
• Melief CJ. (1992) Tumor eradication by adoptive transfer of cytotoxic T lymphocytes. Adv Cancer Res.; 58: 143-75.
• Miller PW, Sharma S, Stolina S et al. (2000) Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum Gene Ther; 11: 53-65.
• Nakamura M, Iwahashi M, Nakamori M, Ueda K, Matsuura I, Noguchi K, Yamaue H. (2002) Dendritic cells genetically engineered to simultaneously express endogenous tumor antigen and granulocyte macrophage colony-stimulating factor elicit potent therapeutic antitumor immunity. Clin Cancer Res.; 8: 2742-9.
• Nawrocki S, Laciak M, Izycki D, Gryska K, Wysocki PJ, Grabarczyk P, Karczewska A, Kaczmarek A, Murawa P, Malicki J, Rose-John S, Mackiewicz A. ( 2001) Humoral responses to melanoma vaccine, genetically modified with interleukin 6 and soluble interleukin 6 receptor. Adv Exp Med Biol.; 495: 411-8.
• Nawrocki S, Mackiewicz A. (1999) Genetically modified tumor vaccines — where are we today. Cancer Treat Rev.; 25: 29-46.
• Nawrocki S, Murawa P, Malicki J, Kapcinska M, Gryska K, Izycki D, Kaczmarek A, Laciak M, Czapczyk A, Karczewska A, Rose-John S, Mackiewicz A. (2000) Genetically modified tumour vaccines (GMTV) in melanoma clinical trials. Immunol Lett.; 74: 81-6.
• Nawrocki S, Wysocki PJ, Mackiewicz A. (2001) Genetically modified tumour vaccines: an obstacle race to break host tolerance to cancer. Expert Opin Biol Ther.; 2: 193-204.
• Nishioka Y, Hirao M, Robbins PD, Lotze MT, Tahara H. (1999) Induction of systemic and therapeutic antitumor immunity using intratumoral injection of dendritic cells genetically modified to express interleukin 12. Cancer Res.; 59: 4035-41.
• Ochsenbein AF, Klenerman P, Karrer U, Ludewig B, Pericin M, Hengartner H, Zinkernagel RM. (1999) Immune surveillance against a solid tumor fails because of immunological ignorance. Proc Natl Acad Sci US A.; 96: 2233-8.
• Ostrand-Rosenberg S, Pulaski BA, Clements VK, Qi L, Pipeling MR, Hanyok LA. (1999) Cell-based vaccines for the stimulation of immunity to metastatic cancers. Immunol Rev.; 170: 101-14.
• Parmiani G, Rodolfo M, Melani C. (2000) Immunological gene therapy with ex vivo gene-modified tumor cells: a critique and a reappraisal. Hum Gene Ther.; 11: 1269-75.
• Peng KW, Vile R. (1999) Vector development for cancer gene therapy. Tumor Targeting.; 4: 3-11.
• Reynolds PN, Zinn KR, Gavryliuk VD, Balyasnikowa IV, Rogers BE, Buchsbaum DJ, Wang MH, Miletich DJ, Grizle WE, Douglas JT, Danilov SM, Curiel DT. (2000). A targetable, injectable adenoviral vector for selective gene delivery to pulmonary endothelium in vivo. Mol Ther.; 2: 562-78.
• Ridge JP, Di Rosa F, Matzinger P. (1998) A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature.; 393: 474-8.
• Rosenberg SA, Aebersold P, Cornetta K, Kasid A, Morgan RA, Moen R, Karson EM, Lotze MT, Yang JC, Topalian SL. (1990) Gene transfer into humans—immunotherapy of patients with advanced melanoma, using tumor-infiltrating lymphocytes modified by retroviral gene transduction. N Engl J Med.; 323: 570-8.
• Schadendorf D. (2002) Gene-based therapy of malignant melanoma. Semin Oncol.; 29: 503-12.
• Schoenberger SP, Toes RE, Van Der Voort EI, Offringa R, Melief CJ. (1998) T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature.; 393: 480-3.
• Shimizu T, Berhanu A, Redlinger JR et al. (2001) Interleukin-12 transduced dendritic cells induce regression of established murine neuroblastoma. JPediatr Surg.; 36: 1285-92.
• Smyth MJ, Godfrey DI, Trapani JA. (2001) A fresh look at tumor immunosurveillance and immunotherapy. Nat Immunol.; 2: 293-9.
• Staveley-O'Carroll K, Sotomayor E, Montgomery J, Borrello I, Hwang L, Fein S, Pardoll D, Levitsky H. (1998) Induction of antigen-specific T cell anergy: An early event in the course of tumor progression. Proc Natl Acad Sci U S A.; 95: 1178-83.
• Tepper RI, Mule JJ. (1994) Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther.; 5: 153-64.
• Todryk SM, Birchall LJ, Erlich R, Halanek N, Orleans-Lindsay JK, Dalgleish AG. (2001) Efficacy of cytokine gene transfection may differ for autologous and allogeneic tumour cell vaccines. Immunology.; 102: 190-8.
• Toes RE, Ossendorp F, Offringa R, Melief CJ. (1999) CD4 T Cells and their role in antitumor immune responses. J Exp Mied.; 189: 753-6.
• Trevor KT, Hersh EM, Brailey J, Balloul JM, Acres B. (2001) Transduction of human dendritic cells with a recombinant modified vaccinia Ankara virus encoding MUC1 and IL-2. Cancer Immunol Immunother.; 50: 397-407.
• Tuting T, Wilson CC, Martin DM et al. (1998) Autologous human monocyte-derived dendritic cells genetically modified to express melanoma antigens elicit primary cytotoxic T cell responses in vitro: enhancement by cotransfection of genes encoding the Th1-biasing cytokines IL-12 and IFN-alpha. J Immunol.; 160: 1139-47.
• Verma I, Somia N. (1997) Gene therapy: Promises, problems and prospects. Nature.; 389: 239-42.
• Vile RG, Nelson JA, Casteleden S, Chong H, Hart IR. (1994) Systemic gene therapy of murine melanoma using tissue specific expression of the HSVtk gene involves an immune component. Cancer Res.; 54: 6228-34.
• Vile RG, Russell SJ, Lemoine NR. (2000) Cancer gene therapy: Hard lessons and new courses. Gene Ther.; 7: 2-8.
• Westermann J, Aicher A, Qin Z et al. (1998) Retroviral interleukin-7 gene transfer into human dendritic cells enhances T cell activation. Gene Ther.; 5: 264-71.
• Wilczyńska U, Kucharska A, Szary J, Szala S. (2001) Combined delivery of an antiangiogenic protein (angiostatin) and and immunomodulatory gene (interleukin-12) in the treatment of murine cancer. Acta Biochim Polon.; 48: 1077-84.
• Wu TC, Guarnieri FG, Staveley-O'Carroll KF, Viscidi RP, Levitsky HI, Hedrick L, Cho KR, August JT, Pardoll DM. (1995) Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. Proc Natl Acad Sci U S A.; 92: 11671-5 .
• Wysocki P, Grabarczyk P, Mackiewicz-Wysocka M, Kowalczyk D, Mackiewicz A. (2002) Genetically modified dendritic cells — a new, promising cancer treatment strategy? Expert Opin Biol Ther.; 2: 835-45.
• Yu D, Thomas-Tikhonenko A. (2001) Intratumoral delivery of an interferon gamma retrovirus-producing cells inhibits growth of a murine melanoma by a non-immune mechanism. Cancer Lett.; 173: 145-54.
• Yu Z, Restifo NP. (2002) Cancer vaccines: progress reveals new complexities. J Clin Invest.; 110: 289-94.